Loading organizations...
§ Private Profile · San Diego, CA, USA
X-Ceptor Therapeutics is a company.
X-Ceptor Therapeutics discovers and develops novel small molecule therapeutics designed to modulate nuclear receptors. The company employs a proprietary "reverse endocrinology" platform, an integrated drug discovery system focused on the nuclear receptor gene family. This approach enables the identification and optimization of compounds targeting various metabolic and cardiovascular disorders, addressing therapeutically rich disease areas.
Founded in 1999, X-Ceptor Therapeutics originated from the scientific insights of Richard Heyman and Ronald Evans. Their core innovation, the "reverse endocrinology" strategy, deviates from traditional methods by initiating drug discovery with a molecular target to rapidly screen for candidate ligands. This parallel approach facilitates target validation and drug development, leveraging their deep expertise in receptor biology and drug design.
The company's products aim to benefit patients suffering from conditions such as metabolic syndrome, lipid disorders, hypertension, and congestive heart failure. X-Ceptor Therapeutics' vision centers on delivering important new medicines to address diseases affecting millions globally, advancing a pipeline of compounds with significant potential to improve patient outcomes in areas of high unmet medical need.
Key people at X-Ceptor Therapeutics.
Key people at X-Ceptor Therapeutics.
X-Ceptor Therapeutics, Inc. was a biopharmaceutical company based in San Diego, California, specializing in the discovery and development of novel small molecule therapeutics that modulate nuclear receptors, particularly orphan nuclear receptors involved in cholesterol metabolism.[1][2][3] It targeted drug candidates for unmet needs in metabolic diseases by interacting with these receptors, serving patients with conditions like dyslipidemia.[3] The company is now out of business, with no active products or ongoing growth momentum reported.[4]
X-Ceptor Therapeutics operated from headquarters at 4757 Nexus Centre Drive Suite 200 in San Diego, focusing on early-stage drug discovery in nuclear receptor modulation.[2] Specific details on founders, founding year, or pivotal early traction are unavailable in public records, and the company attracted investment from firms like Pappas Capital, which highlighted its work on cholesterol-related orphan receptors.[3] Its trajectory ended with closure, as indicated by current status reports.[4]
No data on developer experience, community, or operational metrics, as it was a pre-clinical biotech now defunct.[4]
X-Ceptor rode the early 2000s wave of nuclear receptor research in biotech, amid rising interest in orphan receptors for metabolic diseases like hypercholesterolemia, fueled by market forces around lipid-lowering therapies post-statin era.[3] Its timing aligned with venture funding in San Diego's biotech cluster, influencing the ecosystem by contributing to Pappas Capital's portfolio in targeted drug discovery.[3] Though out of business, it exemplified high-risk innovation in small molecule R&D that advanced knowledge in receptor modulation, even without commercial success.[4]
With X-Ceptor confirmed out of business, no active developments or products are underway, limiting future influence.[4] Trends in nuclear receptor agonists persist in modern biotech for metabolic and liver diseases, but the company's legacy is historical, underscoring risks in early-stage drug discovery. Its specialization may inform ongoing efforts by successors in orphan receptor therapeutics, tying back to its foundational role in cholesterol-focused innovation.[1][3]
